Previous close | 2.9000 |
Open | N/A |
Bid | 1.3500 |
Ask | 5.7000 |
Strike | 2.50 |
Expiry date | 2024-07-19 |
Day's range | 2.9000 - 2.9000 |
Contract range | N/A |
Volume | |
Open interest | 1 |
MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024. "We are excited to
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company’s new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company’s commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access
TELA Bio, Inc. (NASDAQ:TELA) Q1 2024 Earnings Call Transcript May 11, 2024 TELA Bio, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and gentlemen, and welcome to the TELA Bio First Quarter 2024 Earnings Conference Call. […]